Novo Nordisk's new obesity drug data disappoints again, shares fall
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.
Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force behind its strong numbers. It may not be long before Novo Nordisk ...
Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter is ...
“Q4 is always tricky,” Pankit Bhalodia ... leaders of the fourth quarter were familiar—Eli Lilly (45%) and Novo Nordisk (30%). For both companies, the increases were their highest for ...
Goldman Sachs analysts added Novo Nordisk (NVO) to the firm’s European Conviction List as part of its monthly update. Novo Nordisk’s recent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback